Sangamo Therapeutics (SGMOQ) Long-Term Investments (2012 - 2023)

Sangamo Therapeutics has reported Long-Term Investments for 12 years, with the latest figure at $39.0 million in Q2 2023.

• On a quarterly basis, Long-Term Investments fell 18.62% year-over-year to $39.0 million in Q2 2023; TTM through Jun 2023 was $39.0 million, a 18.62% decrease from a year earlier, with the FY2022 full-year figure at $29.8 million, down 66.15% from the prior year.
• Long-Term Investments was $39.0 million for Q2 2023 at Sangamo Therapeutics, up from $35.6 million in the prior quarter.
• The five-year high for Long-Term Investments was $95.6 million in Q3 2021, with the low at $5.0 million in Q1 2020.
• Average Long-Term Investments over 5 years is $45.7 million, with a median of $44.1 million recorded in 2020.
• The sharpest annual moves came in 2019 and 2021: Long-Term Investments plunged 75.28% in 2019, then surged 748.62% in 2021.
• Over 5 years, Long-Term Investments stood at $21.8 million in 2019, then soared by 131.45% to $50.5 million in 2020, then jumped by 74.49% to $88.2 million in 2021, then slumped by 66.15% to $29.8 million in 2022, then jumped by 30.8% to $39.0 million in 2023.
• The last three Long-Term Investments figures came in at $39.0 million (Q2 2023), $35.6 million (Q1 2023), and $29.8 million (Q4 2022), per Business Quant data.